Accuray Incorporated reported a decline in financial performance for the third quarter of fiscal year 2026, with total net revenue of $104.8 million, down 7% from $113.2 million in the same period last year. For the nine months ending March 31, 2026, revenue decreased by 9% to $301.0 million compared to $331.0 million in the prior year. The company's product revenue fell by 13% to $49.7 million for the quarter and by 21% to $131.9 million for the nine-month period, primarily due to lower shipment volumes. Service revenue remained relatively stable, totaling $55.1 million for the quarter and $169.1 million for the nine months, reflecting a slight increase in contract revenues from an expanded installed base.

The company experienced significant changes in its financial metrics compared to the previous fiscal period. Gross profit for the quarter was $25.3 million, a decrease of 20% from $31.6 million a year earlier, while gross profit margins also fell from 27.9% to 24.1%. Operating expenses increased by 12% to $34.4 million, driven by restructuring charges related to a comprehensive transformation plan aimed at enhancing operational efficiency. The net loss for the quarter was $11.8 million, compared to a loss of $1.3 million in the prior year, reflecting the impact of increased interest expenses and restructuring costs.

Strategically, Accuray has been implementing a transformation plan that includes workforce reductions, with approximately 15% of its global workforce eliminated in late 2025. This restructuring is part of a broader initiative to streamline operations and improve accountability. The company also continues to navigate challenges related to supply chain disruptions and inflation, which have adversely affected gross margins and net income. As of March 31, 2026, Accuray's cash and cash equivalents stood at $38.1 million, down from $57.4 million at the end of the previous fiscal year, indicating a tightening liquidity position.

Operationally, Accuray's backlog at the end of the quarter was $356.2 million, a decrease from $452.4 million a year earlier, influenced by cancellations and age-outs of orders. The company reported a book-to-bill ratio of 1.0 for the quarter, indicating that new orders matched revenue recognized, but this was a decline from the previous year's ratio of 1.2. The company continues to focus on its joint venture in China, which is expected to be a significant growth area, although geopolitical tensions and tariff uncertainties pose risks to its operations in that region.

Looking ahead, Accuray anticipates ongoing challenges from macroeconomic conditions, including inflation and supply chain issues, which are expected to impact its financial performance through at least fiscal year 2026. The company is actively evaluating its liquidity and capital requirements in light of these uncertainties and remains committed to executing its transformation plan to position itself for sustainable growth.

About ACCURAY INC

Accuray Incorporated is a radiation therapy company specializing in advanced treatment solutions for cancer and other disorders. Its key products, including the CyberKnife and TomoTherapy platforms, utilize innovative technologies like AI-driven motion tracking for precise, personalized treatments. With a focus on enhancing patient care and expanding market reach, Accuray targets healthcare providers globally, aiming to improve treatment efficiency and outcomes while addressing significant unmet needs in oncology.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.